Background therapy. The present study was conducted to evaluate the efficacy and side effects of topiramate as an add-on therapy in drug-resistant ( intractable) epilepsies .
Materials and methods hospital with refractory epilepsy were enrolled. The study population included 14 girls and 28 boys, aged 1-15 years. Seizure attacks were not controlled despite receiving 4-13 drugs (mean 9). Topiramate was added to the patient's drug in a 4-week titration regimen (1 st week 3, 2 nd week 5, 3 rd week 7, and 4 th week 9mg/kg). Then , after 3 months he/she was reevaluated .
Results progressive myoclonic epilepsy were revealed in 14 (34%), 8(19%), 16(38%), and 4(9%), respectively . After the 3-month add-on therapy with topiramate, 17% became seizure-free and the frequency of seizure attacks decreased by 50% in 26% of the patients , however, attacks were exacerbated in 5%. Fortunately, hematologic, renal or hepatic side effects were not reported, however, mild transient neurologic complications were observed in 12% of the patients .
Conclusion intractable seizures
